Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Effect of Antihypertensive Drugs on Cognition and Behavioral Symptoms of Patients With Alzheimer's Disease: A Meta-Analysis Publisher Pubmed



Rahimi R1 ; Nikfar S1 ; Sadeghi M2 ; Abdollahi M3 ; Moghaddam RH4 ; Farzaei MH2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Evidence-based Evaluation of Cost-Effectiveness and Clinical Outcomes Group (EECECOG), Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Medical Technology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
  3. 3. Toxicology and Diseases Group (TDG), Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Clinical Research Development Center, Imam Ali and Taleghani Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran

Source: Current pharmaceutical biotechnology Published:2021


Abstract

BACKGROUND: It has been found that there is a link between hypertension and elevated risk of Alzheimer's Disease (AD). Herein, a meta-analysis based on Randomized Clinical Trials (RCTs) was used to assess the effect of antihypertensive drugs on cognition and behavioral symptoms of AD patients. METHODS: The three databases, PubMed/Medline, Scopus, and Cochrane Library, were searched up to March 2020. The quality of the studies included in the meta-analysis was evaluated by the Jadad score. Clinical Global Impression of Change (CGIC) included in two studies, Mini-Mental State Examination (MMSE) included in three studies, and Neuropsychiatric Inventory (NPI) in three studies were the main outcomes in this systematic review. RESULTS: Out of 1506 studies retrieved in the databases, 5 RCTs were included and analyzed in the meta-analysis. The pooled mean differences of CGIC, MMSE, and NPI in patients with AD receiving antihypertensive drugs compared to placebo were -1.76 with (95% CI = -2.66 to -0.86; P=0.0001), 0.74 (95% CI = 0.20 to 1.28; P= 0.007), and -9.49 (95% CI = -19.76 to 0.79; P = 0.07), respectively. CONCLUSION: The findings of the present meta-analysis show that antihypertensive drugs may improve cognition and behavioral symptoms of patients with AD. However, more well-designed RCTs with similar drugs are needed to achieve more conclusive results. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.